AstraZeneca’s (NYSE:AZN) Imfinzi (durvalumab) has been approved in the European Union for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin.
The approval was based on positive results from the Phase III CASPIAN trial of Imfinzi plus chemotherapy in ES-SCLC.
It also follows the recommendation for approval by the EMA’s advisory group CHMP in July 2020
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.